Oxidative stress in kidney disease patients
Authors:
J. Vostálová 1; A. Galandáková 1; P. Štrebl 2; J. Zadražil 2; M. Kajabová 3; P. Schneiderka 3
Authors‘ workplace:
Ústav lékařské chemie a biochemie Lékařské fakulty UP Olomouc, přednostka prof. RNDr. Jitka Ulrichová, CSc.
1; III. interní nefrologická, revmatologická a endokrinologická klinika Lékařské fakulty UP a FN Olomouc, přednosta prof. MUDr. Vlastimil Ščudla, CSc.
2; Oddělení klinické biochemie a imunogenetiky FN Olomouc, vedoucí oddělení doc. RNDr. Tomáš Adam, Ph. D.
3
Published in:
Vnitř Lék 2012; 58(3): 202-207
Category:
Reviews
Overview
Patients with chronic kidney disease are exposed to oxidative stress (OS) that contributes to deterioration of health. Decrease in renal excretory capacity contributes to the accumulation of pro-oxidative substances that are detrimental not only to kidney but to the whole organism including the cardiovascular system. Components of antioxidant system play an important role in the elimination of the OS. The monitoring of antioxidant levels and products of oxidative damage in these patients and the correct interpretation of relationship between these markers and the function of kidney and other organs may contribute to the more effective treatment and health improvement of the patients.
Key words:
reactive oxygen and nitrogen species – antioxidants – kidney – dialysis – transplantation – immunosuppressives
Sources
1. Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32: 853–906.
2. Dusilová Sulková S. Klinický význam cévního postižení u diabetiků s onemocněním ledvin – pohled neurologa. Vnitř Lék 2010; 56: 351–355.
3. Zemánek D. Ischemická choroba srdeční a onemocnění ledvin. Kardiol Rev 2005; 4: 191–194.
4. Yeo FE, Villines TC, Bucci JR et al. Cardiovascular risk in stage 4 and 5 nephropathy. Adv Chronic Kidney Dis 2004; 11: 116–133.
5. Rucker D, Tonelli M. Cardiovascular risk and management in chronic kidney disease. Nat Rev Nephrol 2009; 5: 287–296.
6. Himmelfarb J. Relevance of oxidative pathways in the pathophysiology of chronic kidney disease. Cardiol Clin 2005; 23: 319–330.
7. Gutteridge JM. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin Chem 1995; 41: 1819–1828.
8. Babior BM. Superoxide: a two-edged sword. Braz J Med Biol Res 1997; 30: 141–155.
9. Darley-Usmar V, Halliwell B. Blood radicals: reactive nitrogen species, reactive oxygen species, transition metal ions, and the vascular system. Pharm Res 1996; 13: 649–662.
10. Racek J. Oxidační stres a možnosti jeho ovlivnění. Praha: Galén 2003.
11. DeLeo FR, Renee J, McCormick S et al. Neutrophils exposed to bacterial lipopolysaccharide upregulate NADPH oxidase assembly. J Clin Incest 1998; 101: 455–463.
12. Himmelfarb J. Uremic toxicity, oxidative stress, and hemodialysis as renal replacement therapy. Semin Dial 2009; 22: 636–643.
13. Kim HJ, Vaziri ND. Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure. Am J Physiol Renal Physiol 2010; 298: F662–F671.
14. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol 1997; 82: 291–295.
15. Alhamdani MS, Al-Kassir AH, Jaleel NA et al. Elevated levels of alkanals, alkenals and 4-HO-alkenals in plasma of hemodialysis patients. Am J Nephrol 2006; 26: 299–303.
16. Morena M, Delbosc S, Dupuy AM et al. Overproduction of reactive oxygen species in end-stage renal disease patients: a potential component of hemodialysis-associated inflammation. Hemodial Int 2005; 9: 37–46.
17. Steinberg D, Parthasarathy S, Carew TE et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915–924.
18. Locatelli F, Canaud B, Eckardt KU et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18: 1272–1280.
19. Zadák Z, Hyspler R, Tichá A et al. Antioxidants and vitamins in clinical conditions. Physiol Res 2009; 58: S13–S17.
20. Štípek S et al. Antioxidanty a volné radikály ve zdraví a v nemoci. Praha: Grada 2000.
21. Kalousová M, Zima T, Tesař V et al. Advanced glycoxidation end products in chronic diseases – clinical chemistry and genetic background. Mutat Res 2005; 579: 37–46.
22. Descamps-Latscha B, Witko-Sarsat V. Oxidative stress in chronic renal failure and hemodialysis. Nephrologie 2003; 24: 377–379.
23. Capeillere-Blandin C, Deleveau T, Descamps-Latscha B. Structural modification of human β2-microglobulin treated with oxygen-derived radicals. Biochem J 1991; 277: 175–182.
24. Mitrogianni Z, Barbouti A, Galaris D et al. Oxidative modification of albumin in predialysis, hemodialysis, and peritoneal dialysis patients. Nephron Clin Pract 2009; 113: 234–240.
25. Simmons EM, Langone A, Sezer MT et al. Effect of renal transplantation on biomarkers of inflammation and oxidative stress in end-stage renal disease patients. Transplantation 2005; 79: 914–919.
26. Pupim LB, Himmelfarb J, McMonagle E et al. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int 2004; 65: 2371–2379.
27. Marsche G, Frank S, Hrzenjak A et al. Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo. Circ Res 2009; 104: 750–757.
28. Bertram C, Hass R. Cellular responses to reactive oxygen species-induced DNA damage and aging. Biol Chem 2008; 389: 211–220.
29. Klaunig JE, Kamendulis LM, Hocevar BA. Oxidative stress and oxidative damage in carcinogenesis. Toxicol Pathol 2010; 38: 96–109.
30. Valko M, Izakovic M, Mazur M et al. Role of oxygen radicals in DNA damage and cancer incidence. Mol Cell Biochem 2004; 266: 37–56.
31. Herman M, Ori Y, Chagnac A et al. Spontaneous DNA repair increases during hemodialysis. Nephron Clin Pract 2008; 108: c188–c193.
32. Horoz M, Bolukbas FF, Bolukbas C et al. The association of circulating leptin level with peripheral DNA damage in hemodialysis subjects. Clin Biochem 2006; 39: 918–922.
33. Kobras K, Schupp N, Nehrlich K et al. Relation between different treatment modalities and genomic damage of end-stage renal failure patients. Kidney Blood Press Res 2006; 29: 10–17.
34. Stoyanova E, Sandoval SB, Zúñiga LA et al. Oxidative DNA damage in chronic renal failure patients. Nephrol Dial Transplant 2010; 25: 879–885.
35. Racek J, Holeček V. Enzymy a volné radikály. Chem listy 1999; 93: 774–780.
36. Matés JM, Pérez-Gómez C, Núñez de Castro I. Antioxidant enzymes and human diseases. Clin Biochem 1999; 32: 595–603.
37. Tsuchikura S, Shoji T, Shimomura N et al. Serum C-reactive protein and thioredoxin levels in subjects with mildly reduced glomerular filtration rate. BMC Nephrol 2010; 11: 7–13.
38. Kanďár R, Záková P. Allantoin as a marker of oxidative stress in human erythrocytes. Clin Chem Lab Med 2008; 46: 1270–1274.
39. Kohen R, Nyska A. Oxidation of biological systems: oxidative stress phenomena, antioxidants, redox reactions, and methods for their quantification. Toxicol Pathol 2002; 30: 620–650.
40. Sánchez-Lozada LG, Nakagawa T, Kang DH et al. Hormonal and cytokine effects of uric acid. Curr Opin Nephrol Hypertens 2006; 15: 30–33.
41. Lippi G, Montagnana M, Franchini M et al. The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta 2008; 392: 1–7.
42. Puchades Montesa MJ, González Rico MA, Solís Salguero MA et al. Study of oxidative stress in advanced kidney disease. Nefrologia 2009; 29: 464–473.
43. Romeu M, Nogues R, Marcas L et al. Evaluation of oxidative stress biomarkers in patients with chronic renal failure: a case control study. BMC Res Notes 2010; 3: 20–26.
44. Siu YP, Leung KT, Tong MK et al. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 2006; 47: 51–59.
45. Alhamdani MS. Impairment of glutathione biosynthetic pathway in uraemia and dialysis. Nephrol Dial Transplant 2005; 20: 124–128.
46. Armstrong D. Advanced Protocols in Oxidative Stress I. New York: Springer 2008.
47. Armstrong D. Advanced Protocols in Oxidative Stress II. New York: Springer 2010.
48. Cao G, Prior RL. Comparison of different analytical methods for assessing total antioxidant capacity of human serum. Clin Chem 1998; 44: 1309–1315.
49. Wayner DD, Burton GW, Ingold KU et al. Quantitative measurement of the total, peroxyl radical-trapping antioxidant capability of human blood plasma by controlled peroxidation. The important contribution made by plasma proteins. FEBS Lett 1985; 187: 33–37.
50. Kuchta A, Pacanis A, Kortas-Stempak B et al. Estimation of Oxidative Stress Markers in Chronic Kidney Disease. Kidney Blood Press Res 2010; 34: 12–19.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2012 Issue 3
Most read in this issue
- Castleman’s disease
- The role of PET-CT in decision making on the treatment of localized nodular form of pulmonary AL-amyloidosis
- FTO gene and his role in genetic determination of obesity
- Blood pressure changes in chronically haemodialysed patients